The National Cancer Institute (NCI) offers this R21 grant to support exploratory and developmental research in cancer. This funding opportunity focuses on advancing new clinical trials in cancer diagnosis, treatment, imaging, symptom management, and prevention. It also encourages correlative studies, the development of novel therapeutic and preventive agents, and radiotherapy advancements. Innovative preclinical studies, including new clinically-relevant models and imaging technologies, are also a key focus, aiming to lead to first-in-human clinical trials. The R21 mechanism is designed for early-stage, conceptual projects that, despite considerable risk, hold the potential for significant breakthroughs or the development of novel techniques and applications, making a major impact on pre-clinical or clinical cancer research.
Opportunity ID: 356950
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-25-139 |
| Funding Opportunity Title: | NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Nov 04, 2024 |
| Last Updated Date: | May 14, 2025 |
| Original Closing Date for Applications: | Jul 01, 2025 |
| Current Closing Date for Applications: | Sep 07, 2025 |
| Archive Date: | Oct 07, 2025 |
| Estimated Total Program Funding: | $200,000 |
| Award Ceiling: | $275,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | City or township governments For profit organizations other than small businesses Public housing authorities/Indian housing authorities Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) County governments Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Independent school districts Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments State governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: |
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies–including the use of new clinically-relevant models and imaging technologies–which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical). |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-25-139.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Update close date per NOT-CA-25-045. | May 14, 2025 | |
| Nov 04, 2024 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-25-139 |
| Funding Opportunity Title: | NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Nov 04, 2024 |
| Last Updated Date: | May 14, 2025 |
| Original Closing Date for Applications: | Jul 01, 2025 |
| Current Closing Date for Applications: | Sep 07, 2025 |
| Archive Date: | Oct 07, 2025 |
| Estimated Total Program Funding: | $200,000 |
| Award Ceiling: | $275,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | City or township governments For profit organizations other than small businesses Public housing authorities/Indian housing authorities Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) County governments Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Independent school districts Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments State governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: |
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies–including the use of new clinically-relevant models and imaging technologies–which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical). |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-25-139.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-25-139 |
| Funding Opportunity Title: | NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 04, 2024 |
| Last Updated Date: | Nov 04, 2024 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Jul 01, 2025 |
| Archive Date: | Aug 06, 2025 |
| Estimated Total Program Funding: | $200,000 |
| Award Ceiling: | $275,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Special district governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Native American tribal governments (Federally recognized) For profit organizations other than small businesses Small businesses Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts State governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies–including the use of new clinically-relevant models and imaging technologies–which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical). |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-25-139.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Related Documents
Folder 356950 Full Announcement-PAR-25-139 -> PAR-25-139-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00288449 | Jan 13, 2025 | Sep 07, 2025 | View |
Package 1
Mandatory forms
356950 RR_SF424_5_0-5.0.pdf
356950 PHS398_CoverPageSupplement_5_0-5.0.pdf
356950 RR_OtherProjectInfo_1_4-1.4.pdf
356950 PerformanceSite_4_0-4.0.pdf
356950 RR_KeyPersonExpanded_4_0-4.0.pdf
356950 PHS398_ResearchPlan_5_0-5.0.pdf
356950 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
356950 RR_Budget_3_0-3.0.pdf
356950 RR_SubawardBudget30_3_0-3.0.pdf
356950 PHS398_ModularBudget_1_2-1.2.pdf
356950 PHS_AssignmentRequestForm_4_0-4.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
